Association between effective dose of prednisolone, alone or in conjunction with other immunosuppressants, and titre of anti-bullous pemphigoid 180 antibody: A retrospective study of 42 cases

Clinical and Experimental Dermatology

Volumn 36, Issue 5, 2011, Pages 485-488

  Miida, H ^a   Fujiwara, H ^a   Ito, M ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BULLOUS PEMPHIGOID 180 ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BULLOUS PEMPHIGOID; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE INCREASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS; PREDNISOLONE; RETROSPECTIVE STUDIES;

EID: 79959343350     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.04013.x     Document Type: Article

References (15)

1. Wojnarowska F, Kirtschig G, Highet AS et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214-21.
2. Wojnarowska F, Venning VA, Burge SM. Immunobullous diseases (subepidermal immunobullous disease). In: Rook's Textbook of Dermatology (Burns T, Breathnach S, Cox N, Griffiths C, eds). Oxford: Blackwell Science, 2004; 41: 25-59.
3. Giudice GJ, Emery DJ, Zelickson BD et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993; 151: 5742-50.
4. Tsuji-Abe Y, Akiyama M, Yamada Y et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci 2004; 37: 145-9.
5. Feng S, Wu Q, Jin P et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Int J Dermatol 2008; 47: 225-8.
6. Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136: 174-8.
7. Joly P, Roujeau JC, Benichou J et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-7.
8. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75mg/kg/day versus 1.25mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol 1984; 111: 925-8.
9. Thomas I, Khorenian S, Arbesfeld DM. Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol 1993; 28: 74-7.
10. Depaire-Duclos F, Dandurand M, Basset-Seguin N et al. Treatment of bullous pemphigoid with tetracyclines and topical corticosteroids. Eur J Dermatol 1997; 7: 570-3.
11. Fivenson DP, Breneman DL, Rosen GB et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753-8.
12. Jeffes EWB, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol 1989; 14: 132-6.
13. Bouscarat F, Chosidow O, Picard-Dahan C et al. Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34: 683-4.
14. Zhu S, Shimokawa Y, Shoyama H, Tanaka H. A novel analytical ELISA-based methodology for pharmacologically active saikosaponins. Fitoterapia 2006; 77: 100-8.
15. Kishida Y, Miki H, Nishii T et al. Therapeutic effects of Saireito (TJ-114), a traditional Japanese herbal medicine, on postoperative edema and inflammation after total hip arthroplasty. Phytomedicine 2007; 14: 581-6.